Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
From BioNTech SE
Via GlobeNewswire
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
Forecasting The Future: 8 Analyst Projections For BioNTech
Via Benzinga
Market Whales and Their Recent Bets on BNTX Options
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
Via Benzinga
Exposures COVID-19
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV... 
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu... 
Via Benzinga
Exposures COVID-19
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys. 
Via Benzinga
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
Via Benzinga
Exposures COVID-19
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and... 
Via Talk Markets
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
Exposures COVID-19
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.